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Percutaneous Therapies Needed*Jason H. Rogers, MDSEE PAGE 483T ricuspid regurgitation (TR) can arise fromstructural leaﬂet changes (primary TR) as aresult of a variety of causes. More commonly,
TR is secondary (functional TR [FTR]) and occurs
when there is impaired coaptation of normal tricuspid
valve leaﬂets in the setting of right ventricular
enlargement and tricuspid annular dilation. Mild-to-
moderate tricuspid regurgitation is commonly seen
in clinical practice and is generally well tolerated.
More severe TR can develop insidiously and is a
consequence of late-stage myocardial, pulmonary,
and valvular disease. Patients with signiﬁcant FTR
often have multiple comorbidities, and suffer from
reduced cardiac output, congestive hepatopathy,
ascites, peripheral edema, and failure to thrive.
Medical therapy for FTR consists primarily of
intravascular volume management and has limited
efﬁcacy. Surgical correction of FTR is most often
performed during operations for functional mitral
regurgitation (MR) in the setting of left ventricular
heart failure, which results in secondary right ven-
tricular enlargement, unfavorable geometric remod-
eling, and tricuspid annular dilation. Despite the fact
that surgical FTR correction has risen and operative
mortality has decreased over the last decade, surgi-
cal correction of TR remains underutilized (1).
Aggressive treatment of FTR at the time of initial
surgery is important, because reoperation for recur-
rent TR in patients with heart failure can have an in-
hospital mortality up to 35% (2). Surgical correction
of FTR consists of reducing the tricuspid annular
area with ring or suture annuloplasty, thereby
moving the leaﬂets closer together. Despite studies*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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rigid ring annuloplasties, suture and rigid annulo-
plasties are still both employed in the surgical
treatment of TR (3). Current recommendations from
the 2012 European Society of Cardiology and the
European Association for Cardio-Thoracic Surgery (4)
and 2014 American College of Cardiology/American
Heart Association guidelines (5) strongly encourage
the surgical correction of TR in patients undergoing
left-sided valve surgery. Despite the enthusiasm of
these recommendations, the supporting level of evi-
dence is no higher than Level of Evidence: C, high-
lighting the lack of prospective randomized trials.
Because many patients develop recurrent TR over
time, and reoperation is not often performed for
recurrent TR, emerging minimally invasive and
transcatheter methods of FTR correction have the po-
tential to expand therapeutic options and improve
safety.In this issue of JACC: Cardiovascular Interventions,
Rogers et al. (6) from the National Institutes of Health
describe a highly innovative approach to the treat-
ment of FTR using trans-auricular intra-pericardial
tricuspid annuloplasty (TRAIPTA). This transcatheter
procedure consists of performing a controlled punc-
ture into the pericardial space through the anterior
aspect of the right atrial appendage. A “hoop” made
of braided nitinol wire is then deployed within the
pericardial space around the base of the heart and
tensioned to reduce tricuspid annular dimensions,
thereby reducing FTR. TRAIPTA is a novel technique
that is similar to an encircling-type concept (mitral
cerclage) previously reported by this group for the
mitral valve (7). The authors report the technique and
results of TRAIPTA in 16 swine (12 healthy and 4 with
experimentally induced FTR), with high procedural
success and signiﬁcant favorable changes in the
tricuspid annular geometry. The procedure was
FIGURE 1 Transcatheter Therapies for FTR
(A) The TriCinch Gen 1 System (4 Tech, Dublin, Ireland) is a percutaneous approach in which anchors are placed in the inferior vena cava and on
the tricuspid valve annulus. (B) Tension is then applied between the 2 points with a Dacron band leading to a reduction of the tricuspid valve
area and decreased functional tricuspid regurgitation (FTR). (C) The Mitralign device (Tewksbury, Massachusetts), which is used for functional
mitral regurgitation, has been adapted for the treatment of FTR. Two pledgeted anchors are placed. (D) The anchors are tensioned,
which plicates the posterior annulus. (E) The sutures are locked, resulting in bicuspidalization of the tricuspid valve and reduction in FTR.
Yellow arrows show reduction of tricuspid annular dimensions pre- and post-procedure for both devices.
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493reported to be safe in these animals, with no adverse
events and no coronary artery compromise.
Most transcatheter valve therapies have been targeted
atpatientswhoarehigh risk for conventional surgery.This
paradigm has been successful and led to Food and Drug
Administration approval for transcatheter aortic valve
replacement and percutaneous edge-to-edge mitral valve
correction. Because these target populations are frail and
have multiple comorbid conditions, procedural safety
must be a cardinal concern, followedbyefﬁcacy.Although
the TRAIPTA approach is promising, it is fairly invasive
and carries an as yet undeﬁned risk in humans. The in-
vestigators reviewed 14 human cardiac computed to-
mography scans, and all met anatomic criteria for
transatrial pericardial access, although all subjects had at
least 1 epicardial coronaryartery that crossed theprojected
course of the TRAIPTA implant. TRAIPTA involves
circumferential compression of the heart near the atrio-
ventricular groove, and coronary artery compression
would certainly be possible, although this was not seen in
the animal studies. Other transcatheter devices in the
coronary sinus for the treatment of functional MR have
shown us that coronary artery compression is not pre-
dictable, and that compression can occur intra-
procedurally and in follow-up (8,9).
The TRAIPTA procedure involves planned punc-
ture of the right atrial appendage. There have notbeen any other previously described structural heart
procedures using this access route. Clinical experi-
ence with the fragile left atrial appendage (LAA) has
led operators to a “minimal touch” approach for
LAA occlusion procedures. In a multicenter series
describing real-world outcomes of transcatheter LAA
ligation, a procedure that requires “dry” pericardial
access, clinically signiﬁcant pericardial effusions
(10.4%) and major bleeding (9.1%) were not uncom-
mon (10). Patients at high surgical risk with FTR are
fragile as a rule, and procedural complications will
not be well tolerated. Also, given that TRAIPTA will
not be possible in patients with prior pericardiotomy
or pericarditis (and therefore any patient with prior
cardiac surgery), the applicability of this procedure to
a “high-risk population” (many of whom have had
prior sternotomy) could be limited.
There are currently no reports of native trans-
catheter tricuspid valve replacement, but other
emerging transcatheter procedures to address TR
have been reported. For patients with degenerated
tricuspid surgical bioprostheses, tricuspid “valve-
in-valve” therapy can be performed. The most
commonly used devices have been the Melody valve
(Medtronic, Minneapolis, Minnesota), and Edwards
Sapien or Sapien XT valves (Edwards Lifesciences,
Irvine, California). Both valves have comparable
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494efﬁcacy and safety in the short term, but longer-term
data are limited.
Investigators have reported placing transcatheter
valves in the inferior vena cava (IVC) and in some
cases the superior vena cava for the treatment of FTR.
The rationale behind this approach is to reduce the
regurgitant volume and pressure from TR that
reﬂuxes into the IVC. Transcatheter placement of a
custom stented valve in the IVC in a patient with
symptomatic FTR resulted in clinical improvement in
symptoms (11). The Sapien XT valve has also been
used in the IVC and superior vena cava positions with
clinical success to reduce the systemic hemodynamic
effects of severe TR (12). The long-term effects of this
caval stenting approach on right atrial size and right
ventricular function are not known, and long-term
anticoagulation is currently recommended. Despite
conceptual promise, the MitraClip procedure (Abbott,
Abbott Park, Illinois), which has been effective in the
mitral position, has not yet been translated success-
fully for use in the tricuspid position. Challenges to a
tricuspid edge-to-edge repair include the trileaﬂetnature of the tricuspid valve, wide malcoaptation
gaps, and higher chordal density. Other transcatheter
therapies for FTR are currently in development
(Figure 1).
In conclusion, patients with severe FTR are
often highly symptomatic, and operations are not
commonly performed because of high actual or
perceived surgical risk. Many patients undergoing
transcatheter correction of MR or aortic stenosis
with biventricular heart failure and FTR may also
beneﬁt from concomitant TR correction. Random-
ized, controlled trials of tricuspid correction versus
control are needed to solidify the evidence for both
current surgical and future transcatheter approaches.
TRAIPTA encourages us to consider what is possible,
and moves us forward in our efforts to expand
tricuspid valve therapies.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Jason H. Rogers, Division of Cardiovascular Medicine,
4860 Y Street, Suite 2820, Sacramento, California
95817. E-mail: jason.rogers@ucdmc.ucdavis.edu.RE F E RENCE S1. Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV.
Trends and outcomes of tricuspid valve surgery in
North America: an analysis of more than 50,000
patients from the Society of Thoracic Surgeons
Database. Ann Thorac Surg 2013;96:1546–52,
discussion 1552.
2. Bernal JM, Morales D, Revuelta C, Llorca J,
Gutierrez-Morlote J, Revuelta JM. Reoperations
after tricuspid valve repair. J Thorac Cardiovasc
Surg 2005;130:498–503.
3. Navia JL,Nowicki ER, BlackstoneEH, et al. Surgical
management of secondary tricuspid valve regurgi-
tation: annulus, commissure, or leaﬂet procedure?
J Thorac Cardiovasc Surg 2010;139:1473–82.e5.
4. Vahanian A, Alﬁeri O, Andreotti F, et al.
Guidelines on the management of valvular heart
disease (version 2012): the Joint Task Force on
the Management of Valvular Heart Disease of
the European Society of Cardiology (ESC) and
the European Association for Cardio-Thoracic
Surgery (EACTS). Eur J Cardiothorac Surg 2012;
42:S1–44.5. Nishimura RA, Otto CM, Bonow RO, et al. 2014
AHA/ACC guideline for the management of pa-
tients with valvular heart disease: executive
summary: a report of the American College of
Cardiology/American Heart Association Task Force
on Practice Guidelines. J Am Coll Cardiol 2014;63:
2438–88.
6. Rogers T, Ratnayaka K, Sonmez M, et al.
Transatrial intrapericardial tricuspid annuloplasty.
J Am Coll Cardiol Intv 2015;8:483–91.
7. Kim JH, Kocaturk O, Ozturk C, et al. Mitral
cerclage annuloplasty, a novel transcatheter
treatment for secondary mitral valve regurgita-
tion: initial results in swine. J Am Coll Cardiol
2009;54:638–51.
8. Harnek J,Webb JG, Kuck KH, et al. Transcatheter
implantation of the MONARC coronary sinus device
for mitral regurgitation: 1-year results from the
EVOLUTIONphase I study (Clinical Evaluationof the
Edwards Lifesciences Percutaneous Mitral Annulo-
plasty System for the Treatment of Mitral Regur-
gitation). J Am Coll Cardiol Intv 2011;4:115–22.9. Siminiak T, Wu JC, Haude M, et al. Treatment
of functional mitral regurgitation by percutaneous
annuloplasty: results of the TITAN Trial. Eur J
Heart Fail 2012;14:931–8.
10. Price MJ, Gibson DN, Yakubov SJ, et al. Early
safety and efﬁcacy of percutaneous left atrial
appendage suture ligation: results from the U.S.
transcatheter LAA ligation consortium. J Am Coll
Cardiol 2014;64:565–72.
11. LautenA, FerrariM,HekmatK, et al. Heterotopic
transcatheter tricuspid valve implantation: ﬁrst-in-
man application of a novel approach to tricuspid
regurgitation. Eur Heart J 2011;32:1207–13.
12. Laule M, Stangl V, Sanad W, Lembcke A,
Baumann G, Stangl K. Percutaneous transfemoral
management of severe secondary tricuspid regur-
gitation with Edwards Sapien XT bioprosthesis:
ﬁrst-in-man experience. J Am Coll Cardiol 2013;61:
1929–31.
KEY WORDS transcatheter repair,
tricuspid regurgitation, tricuspid valve
